Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go:
TBC
investment:
Withheld
Skinny Tonic (ST) aims to change the traditional soft drink market by creating 100% natural, zero-sugar, zero-calorie soft drinks. The company raised £1.8 million in its first Seedrs raise in January 2020. It also raised £1.75 million in conjunction with the UK Future Fund and received the Food Matters Award for 'New drink product of the year'. ST also launched four flavours into 27 Booths stores in June 2020. It will use the investment to pioneer New Product Development (NPD), achieve British Retail Consortium (BRC) accreditation, continue to invest in staff training and recruitment, launch its fully automated canning and bottling facility, and grow the business across different verticals.
days to go:
Expired
investment:
£2,433,839
TV.FIT is a streaming service and app that allows its users to access 100 hours of health & wellbeing content from global fitness experts & celebrities. Its subscription service is accessible in 66 countries across 6 continents. The platform aims to cater to all aspects of fitness, from mental health support for those who have yet to start to improve their fitness to creating content for those who are already working on their fitness regime. Its programs are created by some of the world’s most well-known fitness figures including George St-Pierre, Caroline Pearce, Gemma Atkinson, and Pierre Pozzuto. The platform has a global multimedia reach of over 8 million followers via partners such as TruFusion and CoolEvents, with another 6 million+ prospective users in the pipeline. TV.FIT also disseminates NHS-recommended mental-health-focused content on its platform. With the funds received, the platform aims to invest 31% of it in marketing, 28% in international content development, 22% in capital reserves, 18% in content production, and 1% towards repayment of debt.
days to go:
Expired
investment:
£2,208,212
MysteryVibe creates doctor-recommended sexual health devices. The company combines research and engineering by onboarding leading doctors to design devices that address major sexual health issues such as erectile dysfunction, dryness and pain during intercourse. MysteryVibe has changed over 50,000 lives in 65 countries, witnessed $1 million worth of direct sales in 2020, and became the first sexual health startup to be featured on a BBC documentary. The company has received 20+ international awards including, the coveted Design Week Awards where its product, 'Crescendo', beat the Apple Watch. MysteryVibe has featured in media entities like Men's Health, Women's Health, The Daily Dot, and Forbes, to name a few. The company will use 25% of the investment to expand and scale its digital marketing campaign, 25% to launch two new products, 25% to expand its team, and 25% on building its inventory.
days to go:
Expired
investment:
£498,020
TheVeganKind is a plant-based supermarket subscription box service that sells different vegan and plant-based products. The company has generated a revenue of £2.5m during Nov 2018-Nov 2019. TheVeganKind had shipped more than 130,000 orders alone in 2019. There are more than 4,500 different vegan and plant-based products in stock. It has been recently voted the UK's Top Online Retailer for Vegan Shopping. TheVeganKind has more than 500,000 social followers across Facebook, Twitter, and Instagram. With the proceeds, the company will allocate 60% of the funds towards marketing and branding; 20% will go towards warehouse expansion, and in increasing its inventory; 20% will go towards operating expenditure and team expansion.
days to go:
Expired
investment:
£669,188
HealthBox Software is a technology company building products for the post-COVID healthcare landscape. Its first product, ClearPass, was met with success. The tool asks an employee a series of screening questions related to COVID-19, including evidence of fever, fatigue, and dry cough, etc. ClearPass has over 400,000 end-users including companies like Johnson Controls, Remy Cointreau and the San Diego School District. HealthBox aims to be a significant contender in the global digital health market that is expected to be worth $600 billion by 2026. The company is on the verge of launching another innovative product, MyHealthBox. It is a consumer-facing digital health app that will allow users to store their medical records, easily accessible 24/7. HealthBox asserts that the app will have an array of features, including AI health assessment services, dietary advice and data-powered lifestyle guidance. The company will use 47% of the investment towards technology and development costs, and 53% towards sales and marketing.
days to go:
Expired
investment:
£144,265
Thalamos is a software solution for completing the Mental Health Act (MHA) forms digitally, across any device. It aims to help those with acute mental illness access care quickly reducing treatment time from 7 days to 27 hours. The company delivers SaaS (Software-as-a-Service) to National Health Service (NHS) Trusts, local authorities and private mental healthcare providers. It also works directly with the UK healthcare regulator, The Care Quality Commission (CQC). Thalamos has over £500,000 of investment raised till date. Pre Covid-19, the company was already working with the CQC and supported them in safely submitting their statutory forms to hospitals across the country. Over 75% of NHS Trusts have received Thalamos' MHA forms in the last 60 days. The company will use 48% of the investment for product development, 20% for customer on-boarding, 16% for business development, and 16% as working capital.
days to go:
Expired
investment:
£290,278
